Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Early-stage in vitro and ex vivo proof-of-concept work demonstrating a novel triple-target CRISPR strategy, not yet tested in vivo or clinically, with no efficacy or safety data in human subjects.
Single-arm phase II trial showing encouraging ORR and PFS in a small cohort, but lacks a control arm and mature OS data; results warrant phase III confirmation but do not yet change practice.